RPV 25 mg

DRUG3 trials

Sponsors

ViiV Healthcare

Conditions

HIV InfectionsInfection, Human Immunodeficiency Virus

Phase 1

Relative Oral Bioavailability Study of Different Fixed Dose Combinations of Dolutegravir and Rilpivirine in Healthy Subjects

CompletedNCT02373930

ViiV HealthcareInfection, Human Immunodeficiency Virus

Start: 2015-02-28End: 2015-09-30Updated: 2016-06-27

Phase 3

Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-2)

CompletedNCT02422797

ViiV HealthcareHIV Infections

Start: 2015-04-21End: 2023-05-25Updated: 2024-09-03

Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-1)

CompletedNCT02429791

ViiV HealthcareHIV Infections

Start: 2015-04-14End: 2023-05-30Updated: 2024-09-03

Related Papers

Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies.

2019-07-1277 citations

Bioequivalence of a Fixed-Dose Combination Tablet of the Complete Two-Drug Regimen of Dolutegravir and Rilpivirine for Treatment of HIV-1 Infection.

2018-08-278 citations

Switch from tenofovir disoproxil fumarate combination to dolutegravir with rilpivirine improves parameters of bone health.

2018-02-0137 citations

Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies.

2018-01-06257 citations